Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo.

about

The anti-cancerous activity of recombinant trichosanthin on prostate cancer cell PC3

P2860

Q36728200-11A4651D-E473-4D69-90F7-F029ECC06195

P2860

Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo.

Item

http://www.wikidata.org/entity/Q44703429

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Tumor necrosis therapy antibod ...... ted antitumor effects in vivo.

@en

Tumor necrosis therapy antibod ...... ted antitumor effects in vivo.

@nl

type

Item

label

Tumor necrosis therapy antibod ...... ted antitumor effects in vivo.

@en

Tumor necrosis therapy antibod ...... ted antitumor effects in vivo.

@nl

prefLabel

Tumor necrosis therapy antibod ...... ted antitumor effects in vivo.

@en

Tumor necrosis therapy antibod ...... ted antitumor effects in vivo.

@nl

P1476

Tumor necrosis therapy antibod ...... ted antitumor effects in vivo.

@en

P2093

Dan Ye

http://www.w3.org/2001/XMLSchema#string

Dianwen Ju

http://www.w3.org/2001/XMLSchema#string

Jiajun Fan

http://www.w3.org/2001/XMLSchema#string

Li Ye

http://www.w3.org/2001/XMLSchema#string

Meiqing Feng

http://www.w3.org/2001/XMLSchema#string

Qun Tao

http://www.w3.org/2001/XMLSchema#string

Xunlong Shi

http://www.w3.org/2001/XMLSchema#string

Zongshu Xian

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors.

By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro.

Design, construction, and characterization of a large synthetic human antibody phage display library.

Antibody-cytokine fusion proteins for the therapy of cancer.

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c

The cancer vaccine roller coaster.

Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta.

Cytokine-based therapy and biochemotherapy for advanced melanoma.

Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome.

Update on the application of interleukin-2 in the treatment of renal cell carcinoma.

P2888

s00253-013-5349-0

P304

4053-4061

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00253-013-5349-0

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yubin Li

Xian Zeng

P577

2013-11-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258922875

http://www.w3.org/2001/XMLSchema#string

P698

24276620

http://www.w3.org/2001/XMLSchema#string

Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo.

about

P2860

P2860

Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698